Abstract. Background. The prevalence of non-alcoholic steatohepatitis (NASH) and chronic obstructive pulmonary disease (COPD) is gaining global significance in the population of economically developed countries with a growing trend in Ukraine [1–3]. In the USA, the number of cases of NAFLD is projected to reach 100.9 million people (35%) by 2030, and the proportion of NASH among these patients will increase to 27% [4]. Unfortunately, in Ukraine, there is no systematic data on the prevalence of NASH that makes it difficult to formulate a prognosis, but

Results. The proposed therapy with antral reduced the intensity of lysis of azoalbumin, azocasein and azocol in patients of group O2: at day 30, the decrease was 1.3, 1.2 and 1.6 times (p < 0.05), respectively, in patients of the group O1: on day 30, the decrease was 1.2, 1.2 and 1.6 times (p < 0.05), respectively, compared to the pre-treatment values. In the group C, the values decreased less intensively (p < 0.05): only the azocol values were likely to change — 1.3 times (p < 0.05) with the presence of a significant difference with the groups O1 and O2 (p < 0.05). Conclusions. The combined administration of antral for 30 days resulted in a significant correction of protease-inhibitory homeostasis in patients with NASH associated with obesity and COPD, which was accompanied by a significant decrease in endotoxicosis (p < 0.05) and damaging effect of systemic proteolysis (p < 0.05).

Keywords: non-alcoholic steatohepatitis; chronic obstructive pulmonary disease; proteolysis; endotoxicosis

Introduction
Over the last few years, there has been an explosive interest of the scientific community in non-alcoholic fatty liver disease (NAFLD) and its progressive stage — non-alcoholic steatohepatitis (NASH) due to their widespread among the population of economically developed countries with a growing trend in Ukraine [1–3]. In the USA, the number of cases of NAFLD is projected to reach 100.9 million people (35%) by 2030, and the proportion of NASH among these patients will increase to 27% [4]. Unfortunately, in Ukraine, there is no systematic data on the prevalence of NASH that makes it difficult to formulate a prognosis, but...
we can definitely speak of a heavy economic burden and an increase in the number of patients with liver cirrhosis, terminal stages of the disease, requiring transplantation, and with hepatocellular carcinoma.

The experience of treating NASH is still small, so the therapy has not yet been developed in detail. The use of drugs with different mechanisms of action is investigated.

There are known results from some studies of predominantly uncontrolled or descriptive nature, as well as small-scale randomized controlled (pilot) trials of several drugs, most of which are based on morphological data [5–8]. Researchers emphasize the reduction ( arresting ) of laboratory and morphological features of NASH activity [9, 10], but the results of pharmacotherapy are ambiguous. Despite the increase in the comorbidity of NASH and chronic obstructive pulmonary disease (COPD), there is a need to conduct studies regarding general mechanisms of development and burden interaction of these nosologies with the development of new correction methods.

According to a number of studies on the use of antral, the remedy promotes the restoration of glycogen and protein-synthesizing function of the liver, improves phospholipid synthesis, activates cytochrome system, stimulates tissue respiration processes, improves energy supply and functioning of hepatocyte monoxygenase system, contributing to the reduction of endotoxicosis intensity [11, 12]. By inhibiting cyclooxygenase and reducing the synthesis of prostaglandins and other mediators of inflammation, antral exerts its anti-inflammatory effect, inhibiting the processes of free radical oxidation and enhancing the processes of neutralization of free radicals, leading to a decrease in the severity of cytolytic syndrome that prevents the destruction of hepatocytes and reduces the intensity of the inflammatory process in the bronchi [13].

In Ukraine, a new phytopreparation has appeared, which improves the lipid spectrum of the blood and has an antioxidant effect protecting low-density lipoprotein cholesterol from destruction by free radicals, reducing hypertriglyceridemia, suppressing excessive platelet aggregation and improving the effectiveness of statin therapy in combined use — phytostatin, which is a mixture of fatty alcohols extracted from the waxy mass of sugar cane [14].

**Purpose.** Determination of the intensity of systemic proteolysis and endogenous intoxication before treatment and the efficacy of the use of antral in patients with NASH against the background of obesity, depending on the comorbidity of COPD.

**Material and methods**

Seventy-six patients with NASH, grade 1 obesity and COPD 2–3 D were screened and divided into 3 groups according to the treatment received. Before treatment, the average activity of cytolytic syndrome (the activity of alanine aminotransferase) was (1.440 ± 0.011) μmol/l/h + 1. The control group (group C) consisted of 23 patients receiving basic treatment for NASH (essential fatty acids complex 300 mg 2 capsules 3 times daily) for 30 days and baseline COPD therapy (budesonide 160 μg/d + formoterol fumarate 4.5 μg/d) by inhalation 2 times a day for 30 days; ipratropium/fenoterol (250/500 μg/ml) by inhalation with a nebulizer twice a day; azithromycin 500 mg once per day for 10 days. Twenty-five patients (group 2 — primary, O1), in addition to similar COPD therapy, for the treatment of NASH, instead of essential fatty acids complex, received antral at a dose of 200 mg 3 times a day for 30 days. The third group (basic, O2) involving 28 patients with NASH, grade 1 obesity and COPD 2–3 D, in addition to similar baseline COPD therapy, for the treatment of NASH, instead of essential fatty acids complex, received antral at a dose of 200 mg 3 times daily and, additionally, policosanol at a dose of 20 mg after the dinner for 30 days. The mean age of the patients was (55.70 ± 3.22) years. The comparison group consisted of 30 apparently healthy individuals (AH).

The diagnosis of NASH was made according to the unified clinical protocol approved by the order of the Ministry of Health of Ukraine No. 826 of 06.11.2014, in the presence of criteria for the exclusion of chronic diffuse liver disease of viral, hereditary, autoimmune or drug genesis as the cause of cytolytic, cholestatic, mesenchymal-inflammatory syndromes, and the results of ultrasonography with shear wave elastography, SteatoTest.

The diagnosis was established and the treatment for COPD was conducted following the clinical guidelines (MOH Order No. 555 of June 27, 2013, taking into account the recommendations of GOLD, 2019).

The obesity was diagnosed according to the classification of the WHO International Obesity Working Group (1997).

The patients were subjected to measurements of height and body weight, their body mass index (BMI) was calculated according to the Kettle formula (1):

\[
BMI = \frac{ масс (кг)}{的高度^2 (м)}.
\] (I)

The diagnosis of obesity was made with BMI higher than 30 kg/m².

On admission to the hospital, the functional state of the liver was determined according to the approval list of activity of enzymes, markers of pigment and nitrogen metabolism, proteinogram, lipogram, ionogram, and calculation of the de Ritis ratio. All the patients underwent anthropometry to determine BMI, waist circumference (WC), hip circumference (HC), and waist/hip index (WHI = WC/HC).

The intensity of endotoxicosis was studied by the content of medium molecular weight peptides (MMWP) by the method of N.I. Gabrielyan at 254 and 280 nm. The proteolytic activity of blood plasma was studied using azocasein (AC) (lysis of high molecular weight proteins), azocoll (CLA) (collagen lysis) using standard reagent kits (Simko Ltd, Lviv).

Statistical analysis of the results was performed according to the type of study conducted and the types of numerical data obtained. The normality of the distribution was checked using the Lilliefors, Shapiro–Wilks tests and the method of direct visual evaluation of the histograms of the distribution of eigenvalues. Quantitative indicators that had a normal distribution are presented as mean (M) ± standard deviation (S). For comparisons of data that had a normal...
Results
The analysis of systemic proteolysis indicators for treatment in patients with NASH, obesity, and COPD indicates that they are significantly higher compared to AHI. Thus, the intensity of azaalbumin and azocasein lysis exceeded that of AHI by 1.4 times ((4.13 ± 0.08 and 3.59 ± 0.03) E440/ml/h vs (2.91 ± 0.06 and 2.59 ± 0.05) E440/ml/h, respectively, compared to AHI, and the intensity of azocol lysis increased by 2.0 times (1.22 ± 0.05 vs 0.61 ± 0.04) E440/ml/h (p < 0.05). At the same time, patients with a comorbid course of NASH and COPD experienced a significant level of endogenous intoxication, which was established by blood levels of MMWP 254 and MMWP 280. In particular, the blood content of MMWP 254 was 1.8 times increased ((0.43 ± 0.03) vs (0.240 ± 0.001) c.u./l, respectively, and MMWP 280 — by 2.0 times ((0.51 ± 0.02) vs (0.260 ± 0.001) c.u./l compared to AHI) (p < 0.05) (Table 1).

The analysis of the effect of antral complex therapy on the state of endotoxins and the proteinase-inhibitory system (Table 1) indicates a higher degree of efficacy in the groups of patients O1 and O2 since only these groups developed a significant decrease in the intensity of lysis of AA, AC, CLA (p < 0.05).

Thus, the maximum effect on the lysis intensity of AA, AC, and azocol was achieved using the therapy in patients of the group O2: on day 30, the decrease was 1.3 (from (4.13 ± 0.08) to (3.25 ± 0.03) E440/ml/h), 1.2 ((3.57 ± 0.06) vs (4.12 ± 0.07) E440/ml/h), 1.2 ((3.60 ± 0.03) vs (3.02 ± 0.10) E440/ml/h), and 1.6 ((0.78 ± 0.01) vs (1.23 ± 0.06) E440/ml/h) times, respectively (p < 0.05), compared with the values before treatment. The effect of treatment on patients in group O1 was also significant: on day 30, the decrease was 1.2 ((3.57 ± 0.06) vs (4.12 ± 0.07) E440/ml/h), 1.2 ((3.60 ± 0.03) vs (3.02 ± 0.10) E440/ml/h), and 1.6 ((0.78 ± 0.01) vs (1.23 ± 0.06) E440/ml/h) times, respectively (p < 0.05), compared with the values before treatment. In the group C, the decrease also occurred, but much slower and less intensive (p < 0.05) (Table 1): only the CLA indicator changed significantly — 1.3 times decreased (from (1.22 ± 0.05) to (0.93 ± 0.02) E440/ml/h) (p < 0.05) compared with the values in the groups O1 (0.78 ± 0.01) and O2 (0.75 ± 0.01) E440/ml/h (p < 0.05).

In patients with NASH with COPD received the therapy programs containing antral, the degree of endogenous intoxication also reduced more effectively. Thus, in patients of groups O1 and O2, the blood levels of MMWP 254 decreased after treatment by 1.2 (from (0.42 ± 0.03) to (0.34 ± 0.01) c.u./l) and 1.3 (from (0.43 ± 0.04) to (0.32 ± 0.01) c.u./l) times, respectively (p < 0.05), and MMWP 280 — by 1.8 (from (0.52 ± 0.01) to (0.28 ± 0.01) c.u./l) and 2.0 (from (0.51 ± 0.02) to (0.27 ± 0.01) c.u./l) times, respectively (p < 0.05) with normalization of the values against 1.3 times ((0.43 ± 0.03) vs (0.38 ± 0.02) c.u./l after the therapy) in the group C (p < 0.05) (Table 1). The complex therapy of patients with NASH associated with obesity and COPD which included antral in combination with policosanol helped to reduce the damaging effect on systemic proteolytic and endotoxicosis in patients with NASH, COPD and obesity.

Discussion
Detoxification function of the liver requires intensive aerobic metabolism to produce sufficient ATP in the mitochondria of hepatocytes, which leads to the constant formation of reactive oxygen species (ROS) [15]. It should be noted that damage to hepatocytes with the presence of in-

Table 1 — Indicators of intensity of systemic endotoxins, plasma proteolysis, collagenolysis in patients with non-alcoholic steatohepatitis accompanied by obesity and COPD in the dynamics of treatment (M ± m)

| Values               | AHI   | Group C (n = 23) Before treatment | Group O1 (n = 25) Before treatment | Group O2 (n = 28) Before treatment | Group C (n = 23) In 30 days | Group O1 (n = 25) In 30 days | Group O2 (n = 28) In 30 days |
|----------------------|-------|----------------------------------|-----------------------------------|-----------------------------------|-----------------------------|----------------------------|----------------------------|
| Azoalbumin lysis, E440/ml/h | 2.91 ± 0.06 | 4.15 ± 0.08*                        | 3.60 ± 0.07*                        | 4.12 ± 0.07*                        | 3.57 ± 0.06* **                        | 4.13 ± 0.08*                        | 3.25 ± 0.03* **                        |
| Azocasein lysis, E440/ml/h | 2.59 ± 0.05 | 3.59 ± 0.03*                        | 3.43 ± 0.12*                        | 3.60 ± 0.03*                        | 3.02 ± 0.10* **                        | 3.54 ± 0.02*                        | 2.91 ± 0.07* **                        |
| Azocol lysis, E440/ml/h  | 0.61 ± 0.04 | 1.22 ± 0.05*                        | 0.93 ± 0.02*                        | 1.23 ± 0.06*                        | 0.78 ± 0.01* **                        | 1.22 ± 0.04*                        | 0.75 ± 0.01* **                        |
| MMWP 254, c.u./l        | 0.240 ± 0.001 | 0.43 ± 0.03*                        | 0.38 ± 0.02*                        | 0.42 ± 0.03*                        | 0.34 ± 0.01* **                        | 0.43 ± 0.04*                        | 0.32 ± 0.01* **                        |
| MMWP 280, c.u./l        | 0.260 ± 0.001 | 0.51 ± 0.02*                        | 0.39 ± 0.02*                        | 0.52 ± 0.01*                        | 0.28 ± 0.01* **                        | 0.51 ± 0.02*                        | 0.27 ± 0.01* **                        |

Notes: group C (control) — patients with NASH who received essential fatty acids complex; group O1 (basic) — patients with NASH who received antral; group O2 — patients with NASH who received antral and phytostatin; * — the difference is probable compared with the AHI group (p < 0.05); ** — probable difference compared with the values before treatment (p < 0.05); *** — probable difference compared with the values after treatment in patients of group C (p < 0.05); **** — probable difference compared with the values after treatment in patients of group O1 (p < 0.05) with the values in patients of group O2 (p < 0.05).

Vol. 54, No. 2, 2020 www.gastro.org.ua, http://gastro.zaslavsky.com.ua
flammation can significantly increase the intensity of free radical processes, both in each hepatocyte and in the organ as a whole. These processes further intensify under the conditions of hypoxia caused by lung damage [16]. Oxidative stress leads to an increase in the production of ROS and, as a consequence, the oxidative modification of proteins (OMP): their aggregation and fragmentation, which is accompanied by irreversible changes in the physicochemical and biological properties of the protein molecule. It is known from the existing literature on OMP processes that proteins in which their oxidative modification takes place are much easier to proteolysis [17].

During the study, we found a significant increase in proteolysis (lysis intensity of AC, AA, CLA) in the groups before treatment compared to the AHI group (p < 0.05). In our opinion, the activation of some proteolytic enzymes and their involvement in the processes of degradation of protein components are affected by lysosomal proteases, which after being exposed to free radical oxidation of lipids and oxidative modification of proteins into cells are released from them upon their destruction. Peptide hydrolase released from cells catalyzes specific reactions of limited proteolysis and, in our view, activates inactive precursors of enzymes and isolates specific inhibitors of proteolysis [18–20].

Therefore, in case of NASH associated with obesity and comorbid COPD, the development of an imbalance of the protease-inhibitory system is caused by the uncontrolled elevation in the proteolytic activity of blood plasma.

The degree of endogenous intoxication is to depend not only on the severity and nature of inflammation in the lungs but also on the functional state of the hepatic detoxification system [21, 22], which coincides with the data of our study. A significant level of endotoxicosis, which we established for blood levels of MMWP 254 and MMWP 280, was observed in patients with comorbid NASH, obesity and COPD compared with the AHI group (p < 0.05). There is no room for doubt the fact of the involvement of membrane destructive phenomena in hepatocytes, that makes it possible to correct this type of comorbidity using the drugs with a membrane-stabilizing effect. Antral exhibits such properties [23].

In the groups of patients who received antral for a hepatoprotective therapy (O1 and O2), the degree of endogenous intoxication decreased, there was a significant reduction in the intensity of lysis of AA, AC, and collagen (p < 0.05). Due to stimulation of β-oxidation of fatty acids and influence on the synthesis of phospholipids, antral improves energy processes in cells and arranges the functioning of monooxygenase systems, as a consequence of which the hepatocytes reduce the accumulation of fat, the degree of damage to hepatic cells decreases. There are also data on the effect of antral on immune regulation, namely the effect on T-helper cells and the decrease in the level of circulating immune complexes that contributes to the reduction of the expression of metabolic toxicity [24]. Regarding the combination of antral with policosanol, we registered the best corrective effect on the proteolysis system, namely a probable decrease in the intensity of azoalbumin lysis (p < 0.05).

Prospects for further research in this direction is a further study of the effect of antral and policosanol on the dynamics of clinical, biochemical syndromes of NASH with comorbid COPD on day 60, 90 and 120 of administration, as well as to study the long-term effects of the course of treatment.

Conclusions

1. Patients with non-alcoholic steatohepatitis, obesity and COPD comorbidity showed a significant increase in the intensity of endogenous intoxication with accumulation of medium molecular weight peptides 254 and 280 in the blood (1.8 and 2.0 times, respectively; p < 0.05), which was accompanied by activation of proteolysis (1.4–2.0 times; p < 0.05).

2. Administration of hepatoprotector antral within 30 days led to a significant correction of the damaging effect on the proteolysis system in patients with NASH, obesity and COPD with a significant decrease in the blood content of azoalbumin, azocasein and collagenolytic activity (p < 0.05), accompanied by a significant decrease in endotoxicosis (p < 0.05).

3. Improvements in the effectiveness of NASH and COPD treatment with combined administration of antral and policosanol on the state of proteolysis and endogenous intoxication have been registered by the intensity of azoalbumin lysis (p < 0.05).

Conflict of interests. Authors declare the absence of any conflicts of interests and their own financial interest that might be construed to influence the results or interpretation of their manuscript.

References

1. Anokhina GA. Non-alcoholic liver disease multi-systemic metabolic disease: prevention and treatment. Praktikujuchiy likar. 2018;7(3):35-40. (in Ukrainian).
2. Hukhlisha OS, Antonov AA, Mandryk OJ e, Grynyjuk OJ e. Nealkogol'na zhyrova hvoroba pechinky ta komorbidni stany: osbolyvosti patogenezu, kliniky, diagnostyky, likuvannja: kolektynva monografija [Non-alcoholic fatty liver disease and comorbid conditions: features of pathogenesis, clinic, diagnosis, treatment: collective monograph]. Chernivtsi; 2018. 58-61 pp. (in Ukrainian).
3. Kohyliaik NM, Dynnyk OB, Kyriienko DV. Current approaches to the diagnosis and screening for metabolic disorders in patients with nonalcoholic fatty liver disease. Mіžnarodnій endokrinologічній журнал. 2015;5(69):89-99. doi:10.22141/2224-072. (in Ukrainian).
4. Yonossi ZM, Blissed T, Blissed R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577-1586. doi:10.1002/hep.28785.
5. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908-922. doi:10.1038/s41591-018-0104-9.
6. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263-2273. doi:10.1001/ jama.2015.5370.
7. European Association for the Study of the Liver (EASL);
Інтенсивність системного протеолізу та ендотоксикозу в динаміці лікування гепатопротекторами хворих на неалкогольний стеатогепатит на тлі ожиріння за коморбідності з хронічним обструктивним захворюванням легень

Резюме. Актуальність. Поширеність захворюваності на неалкогольний стеатогепатит (НАСГ) та хронічне обструктивне захворювання легень (ХОЗЛ) набуває глобального значення серед населення економічно розвинених країн світу з тенденцією зростання і в Україні. Мета дослідження: визначення інтенсивності системного протеолізу та ендотоксикозу в динаміці лікування гепатопротекторами у хворих на неалкогольний стеатогепатит на тлі ожиріння та коморбідності з хронічним обструктивним захворюванням легень.

Матеріали та методи. 76 хворих на НАСГ, ожиріння 1 ст. та ХОЗЛ 2–3 D проходили обстеження та були розподілені на 3 групи залежно від призначеного терапевтичного комплексу.

Висновки. У першої групи — контрольної (К) — увійшло 23 хворих, які отримували базисну терапію НАСГ (комплекс есенціальних фосфоліпідів 300 мг по 2 капсули 3 рази на день) упродовж 30 днів та базисну терапію ХОЗЛ. 25 хворих (група 2 — основна, О1), крім аналогічної терапії ХОЗЛ, для лікування НАСГ замість комплексу есенціальних фосфоліпідів отримували антралем 200 мг 3 рази на день упродовж 30 днів. Третій хвори (основна, О2) — 28 хворих, крім аналогічної терапії ХОЗЛ, для лікування НАСГ замість комплексу есенціальних фосфоліпідів отримували антралем 200 мг 3 рази на день та додатково полікозанол 20 мг після вечірнього випадання 30 днів. Групу порівняння становили 30 практично здорових осіб.

Закінчення. Запропонована терапія антралем вплинула на зменшення інтенсивності лізису азоальбуміну, вплинула на зменшення інтенсивності лізису азоальбуміну, збільшення інтенсивності системного протеолізу та ендотоксикозу в динаміці лікування гепатопротекторами.

Література. Додаткові дані на звернення. 20.04.2020

Accepted 12.05.2020
1,6 раза відповідно (р < 0,05) порівняно з величинами до лікування. У групі К зниження відбувається менш інтенсивно (р < 0,05): вірогідно зменшується лише показник лізису азоколу — знизився в 1,3 раза (р < 0,05) за наявності вірогідної різниці з показниками у групах О1 та О2 (р < 0,05). **Висновки.** Призначення антраля упродовж 30 днів призвело до істотної корекції протеіназо-інгібіторного гомеостазу у хворих на НАСГ із ожирінням та ХОЗЛ, що супроводжувалося вірогідним зниженням ендотоксикозу (р < 0,05) та ушкоджувальної дії системного протеолізу (р < 0,05).

**Ключові слова:** неалкогольний стеатогепатит; хронічне обструктивне захворювання легень; протеоліз; ендотоксикоз

Хухлина О.С., Грінюк О.Е., Ляхович О.Д.
ВГУ України «Буковинський державний медичний університет», г. Чернівці, Україна

**Резюме. Актуальність.** Розповсюдженість хворобами печінки і жовчовивідної системи при неалкогольному стеатогепатиті (НАСГ) та хронічним обструктивним патологічним станом органів дихання в Україні приводить до значного зростання смертності. Особливу вагу має хвороба при відносній рідкості в Україні, а саме хронічний обструктивний захворювання легень (ХОЗЛ) та неалкогольний стеатогепатит (НАСГ). Об’єкт дослідження: вивчення динаміки системного протеолізу та ендотоксикозу у хворих на НАСГ з ожирінням і ХОЗЛ.

**Матеріали і методи.** Вивчення проводили на 76 хворих з алерганічним стеатогепатитом (звичайно на фоні ожиріння ст. 1) та ХОЗЛ (ст. 2–3) у віці 18–65 років, які проходили лікування в структурних одиницях Чернівецької обласної клінічної лікарні. Хворих розподілили на 3 групи: контрольну (К) — 23 хворих з базисними терапевтичними процедурами (комплекс фосфоліпідів 300 мг на кожні 2 капсули 3 рази в день на протязі 30 днів) та основну (О1) — 25 хворих з антралем 200 мг на кожні 3 рази в день на протязі 30 днів.

**Результати.** У контрольній групі (К) на протязі 30 днів у всіх хворих не виявлено статистично значущих змін величин системного протеолізу та ендотоксикозу. У групі О1 з базисною терапією та антралем вірогідно змінилися показники протеолізу: лізис азоглюбу- мина знизився в 1,3 раза (р < 0,05) при наявності достовірної різниці з показниками у групах О2, С1 та О2 (р < 0,05).

**Висновки.** Назначення антралу на фоні базисної терапії привело до істотної корекції протеіназо-інгібіторного гомеостазу у хворих відносно реальної дії системного протеолізу (р < 0,05).

**Ключові слова:** неалкогольний стеатогепатит; хронічна обструктивна болезнь легких; протеоліз; ендотоксикоз

**106** **Gastroenterologia, ISSN 2308-2097 (print), ISSN 2518-7880 (online)** **Vol. 54, No. 2, 2020**